Crossmark

Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis

Crossref DOI link: https://doi.org/10.1007/s00393-020-00750-1

Published Online: 2020-02-13

Published Print: 2020-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Young Ho

Song, Gwan Gyu
License Information

Text and Data Mining valid from 2020-02-13

Version of Record valid from 2020-02-13
More Information

Article History

First Online: 13 February 2020

Compliance with ethical guidelines

:

: Y.H. Lee and G.G. Song have no financial or non-financial conflict of interest to declare.

: For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.

Document is current

Any future updates will be listed below